Sonoma Pharmaceuticals, Inc.
SNOANasdaq
$1.21
↓ -0.8%Jul 17 close · end-of-day
Price
1Y↓ -66.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.0M
Enterprise Value
-$139,360.00
P/E
—
P/S
0.1
P/B
0.7
EV/EBITDA
—
PEG
—
FCF Yield
-202.4%
Dividend Yield
—
Revenue (TTM)
$19.5M
Net Income (TTM)
-$3.2M
Free Cash Flow (TTM)
-$4.1M
Gross Margin
38.0%
Operating Margin
-12.6%
Net Margin
-16.3%
ROE
-102.6%
ROIC
-211.8%
Debt / Equity
0.1
Net Cash
$2.2M
Return 1Y
-66.2%
Company profile
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, a prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses. It also offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites.
- CEO
- Amy M. Trombly
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 180
- Headquarters
- Colorado
- Website
- sonomapharma.com
Earnings
SNOA Q4 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$5.6M↑ +48.1%
Diluted EPS-$0.33↑ +43.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| Revenue | $18.6M | $12.6M | $13.3M | $12.7M | $14.3M | $19.5M |
| Gross profit | $6.6M | $4.0M | $4.5M | $4.7M | $5.5M | $7.4M |
| Operating income | -$3.4M | -$5.9M | -$4.6M | -$4.7M | -$3.7M | -$2.5M |
| Net income | -$4.0M | -$5.1M | -$5.2M | -$4.8M | -$3.5M | -$3.2M |
| Diluted EPS | — | -$1.92 | -$1.52 | -$10.63 | -$2.79 | -$1.89 |
| Operating cash flow | -$3.4M | -$4.2M | -$6.2M | -$2.4M | -$88,000.00 | -$3.9M |
| Free cash flow | -$3.6M | -$4.4M | -$6.4M | -$2.4M | -$168,000.00 | -$4.1M |
| Gross margin | 35.2% | 31.6% | 33.7% | 37.3% | 38.2% | 38.0% |
| Operating margin | -18.5% | -46.6% | -34.4% | -36.9% | -26.0% | -12.6% |
| Net margin | -21.2% | -40.3% | -38.8% | -38.0% | -24.2% | -16.3% |
| Line item | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.4M | $3.6M | $3.6M | $3.8M | $4.0M | $5.6M | $4.3M | $5.6M |
| Gross profit | $1.3M | $1.4M | $1.3M | $1.5M | $1.5M | $2.1M | $1.6M | $2.2M |
| Operating income | -$1.2M | -$850,000.00 | -$1.0M | -$656,000.00 | -$1.1M | -$337,000.00 | -$678,000.00 | -$351,000.00 |
| Net income | -$1.1M | -$610,000.00 | -$928,000.00 | -$776,000.00 | -$1.2M | -$534,000.00 | -$819,000.00 | -$581,000.00 |
| Diluted EPS | -$1.34 | -$0.59 | -$0.63 | -$0.23 | -$0.76 | -$0.32 | -$0.48 | -$0.33 |
| Operating cash flow | -$912,000.00 | $354,000.00 | $565,000.00 | -$95,000.00 | -$2.0M | -$635,000.00 | -$764,000.00 | -$519,000.00 |
| Free cash flow | -$917,000.00 | $328,000.00 | $563,000.00 | -$142,000.00 | -$2.1M | -$645,000.00 | -$811,000.00 | -$548,000.00 |
| Gross margin | 38.5% | 38.0% | 35.6% | 40.7% | 36.5% | 37.8% | 37.9% | 39.2% |
| Operating margin | -34.6% | -23.7% | -28.9% | -17.5% | -27.3% | -6.0% | -15.6% | -6.3% |
| Net margin | -33.7% | -17.0% | -26.0% | -20.7% | -30.9% | -9.5% | -18.8% | -10.4% |
Company news
Jun 16, 2026
Apr 24, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.